Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06271265
PHASE1

Study to Evaluate the Pharmacokinetics and Safety of EXPAREL for Postoperative Analgesia in Subjects Undergoing Cardiac Surgery

Sponsor: Pacira Pharmaceuticals, Inc

View on ClinicalTrials.gov

Summary

This Phase 1, multicenter, open-label, randomized, bupivacaine-controlled study is designed to evaluate the pharmacokinetics (PK) and safety of EXPAREL vs. bupivacaine HCl for postsurgical analgesia in pediatric subjects aged 0 to less than 6 years of age undergoing cardiac surgery, utilizing local infiltration analgesia (LIA).

Official title: A Multicenter, Open-label, Randomized, Bupivacaine-Controlled Study to Evaluate the Pharmacokinetics and Safety of EXPAREL for Postoperative Analgesia in Subjects Aged 0 to Less Than 6 Years Undergoing Cardiac Surgery

Key Details

Gender

All

Age Range

0 Years - 6 Years

Study Type

INTERVENTIONAL

Enrollment

48

Start Date

2024-03-29

Completion Date

2027-01

Last Updated

2025-12-29

Healthy Volunteers

No

Interventions

DRUG

EXPAREL

A single dose of EXPAREL Injectable Product via LIA

DRUG

bupivacaine

A single dose of 0.25% bupivacaine via LIA

Locations (5)

Indiana University Health, Riley Hospital For Children

Indianapolis, Indiana, United States

St. Louis Children's Hospital (SLCH)

St Louis, Missouri, United States

Duke University Health System

Durham, North Carolina, United States

University of Oklahoma (OU) - Medical Center - The Children's Hospital

Oklahoma City, Oklahoma, United States

The University of Texas Health Science Center at Houston (UTHSC-H) - McGovern Medical School

Houston, Texas, United States